^
    1year
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (clinicaltrials.gov)
    P1, N=24, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD276 (CD276 Molecule)
    |
    TAA6-CAR-T
    over1year
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    TAA6-CAR-T
    almost2years
    Preconditioning with irradiation enhances efficacy of B7-H3-CAR-T in treating solid tumor models (ESMO 2022)
    Methods A humanized B7-H3 scFv sequence CAR-T was constructed (named TAA06)...Conclusions This study demonstrated that pre-treatment with local irradiation significantly enhanced the ability of CAR-T to infiltrate and kill tumors. The efficacy of combination therapy to treat solid tumors in patients will have to be investigated.
    Preclinical • IO biomarker
    |
    CD276 (CD276 Molecule)
    |
    CD276 expression
    |
    TAA6-CAR-T
    over2years
    A Clinical Trial of TAA06 Injection in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Clinical • New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    TAA6-CAR-T
    3years
    Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Yunhui Zong
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    CD276 expression
    |
    TAA6-CAR-T